# Talphera, Inc.: financial statements, quarterly

TLPH · Nasdaq · CIK 1427925 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tlph.md) · [Financials](/companies/tlph/financials.md) · [Filings](/companies/tlph/filings.md) · [Insiders](/companies/tlph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tlph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [117](/filings/0001437749-24-034965.md) | [281 d](/filings/0001437749-25-010250.md) | [0.0](/filings/0001437749-25-016898.md) | [0.0](/filings/0001437749-25-027002.md) | [0.0](/filings/0001437749-25-034499.md) | [0.0 d](/filings/0001437749-26-009387.md) | [27.0](/filings/0001437749-26-016748.md) | [0.0](/filings/0001437749-26-027316.md) | [1.0](/filings/0001437749-25-034499.md) | [0.0 d](/filings/0001437749-26-009387.md) | [0.0](/filings/0001437749-26-016748.md) | [0.0](/filings/0001437749-26-027316.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,178](/filings/0001437749-24-034965.md) | [1,769 d](/filings/0001437749-25-010250.md) | [1,433](/filings/0001437749-25-016898.md) | [1,909](/filings/0001437749-25-027002.md) | [2,053](/filings/0001437749-25-034499.md) | [1,323 d](/filings/0001437749-26-009387.md) | [1,169](/filings/0001437749-26-016748.md) | [1,500](/filings/0001437749-26-027316.md) | [1,803](/filings/0001437749-25-034499.md) | [1,561 d](/filings/0001437749-26-009387.md) | [1,650](/filings/0001437749-26-016748.md) | [1,690](/filings/0001437749-26-027316.md) |
| Selling, general and administrative | $k | [2,248](/filings/0001437749-24-034965.md) | [2,795 d](/filings/0001437749-25-010250.md) | [2,804](/filings/0001437749-25-016898.md) | [2,361](/filings/0001437749-25-027002.md) | [1,696](/filings/0001437749-25-034499.md) | [1,673 d](/filings/0001437749-26-009387.md) | [1,774](/filings/0001437749-26-016748.md) | [2,193](/filings/0001437749-26-027316.md) | [1,620](/filings/0001437749-25-034499.md) | [1,892 d](/filings/0001437749-26-009387.md) | [2,298](/filings/0001437749-26-016748.md) | [2,234](/filings/0001437749-26-027316.md) |
| Operating income | $k | not reported | not reported | not reported | [(4,270)](/filings/0001437749-25-027002.md) | [(3,749)](/filings/0001437749-25-034499.md) | [(2,996) d](/filings/0001437749-26-009387.md) | [(2,916)](/filings/0001437749-26-016748.md) | [(3,693)](/filings/0001437749-26-027316.md) | [(3,422)](/filings/0001437749-25-034499.md) | [(3,453) d](/filings/0001437749-26-009387.md) | [(3,948)](/filings/0001437749-26-016748.md) | [(3,924)](/filings/0001437749-26-027316.md) |
| Interest expense | $k | [0.0](/filings/0001437749-23-031742.md) | [0.0 d](/filings/0001437749-24-006849.md) | [0.0](/filings/0001437749-24-016694.md) | [0.0](/filings/0001437749-24-026801.md) | [0.0](/filings/0001437749-24-034965.md) | [0.0 d](/filings/0001437749-25-010250.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [2.0](/filings/0001437749-24-034965.md) | [(5.0) d](/filings/0001437749-25-010250.md) | not reported | [0.0](/filings/0001437749-24-026801.md) | [0.0](/filings/0001437749-24-034965.md) | [0.0 d](/filings/0001437749-26-009387.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,357)](/filings/0001437749-24-034965.md) | [(4,517) d](/filings/0001437749-25-010250.md) | [(3,954)](/filings/0001437749-25-034499.md) | [(3,827)](/filings/0001437749-25-034499.md) | [(3,353)](/filings/0001437749-25-034499.md) | [(1,870) d](/filings/0001437749-26-009387.md) | [(2,593)](/filings/0001437749-26-027316.md) | [(3,489)](/filings/0001437749-26-027316.md) | [(4,436)](/filings/0001437749-25-034499.md) | [(3,772) d](/filings/0001437749-26-009387.md) | [(2,556)](/filings/0001437749-26-027316.md) | [(4,312)](/filings/0001437749-26-027316.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001437749-23-031742.md) | not reported | [(0.16)](/filings/0001437749-25-016898.md) | not reported | not reported | not reported | [(0.10)](/filings/0001437749-25-016898.md) | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.08)](/filings/0001437749-24-034965.md) | not reported | [(0.16)](/filings/0001437749-25-016898.md) | [(0.15)](/filings/0001437749-25-027002.md) | [(0.13)](/filings/0001437749-25-034499.md) | not reported | [(0.10)](/filings/0001437749-26-016748.md) | [(0.10)](/filings/0001437749-26-027316.md) | [(0.11)](/filings/0001437749-25-034499.md) | not reported | [(0.04)](/filings/0001437749-26-016748.md) | [(0.06)](/filings/0001437749-26-027316.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [13.4](/filings/0001437749-23-031742.md) | [5.7](/filings/0001437749-25-010250.md) | [12.1](/filings/0001437749-24-016694.md) | [13.4](/filings/0001437749-24-026801.md) | [11.1](/filings/0001437749-24-034965.md) | [8.9](/filings/0001437749-26-009387.md) | [5.4](/filings/0001437749-25-016898.md) | [6.8](/filings/0001437749-25-027002.md) | [3.5](/filings/0001437749-25-034499.md) | [5.9](/filings/0001437749-26-027316.md) | [3.8](/filings/0001437749-26-016748.md) | [0.7](/filings/0001437749-26-027316.md) |
| Current assets | $m | [14.4](/filings/0001437749-23-031742.md) | [11.6](/filings/0001437749-25-010250.md) | [20.0](/filings/0001437749-24-016694.md) | [16.0](/filings/0001437749-24-026801.md) | [12.2](/filings/0001437749-24-034965.md) | [9.4](/filings/0001437749-26-009387.md) | [6.2](/filings/0001437749-25-016898.md) | [7.7](/filings/0001437749-25-027002.md) | [21.9](/filings/0001437749-25-034499.md) | [20.9](/filings/0001437749-26-027316.md) | [21.3](/filings/0001437749-26-016748.md) | [18.0](/filings/0001437749-26-027316.md) |
| Total assets | $m | [23.3](/filings/0001437749-23-031742.md) | [20.4](/filings/0001437749-25-010250.md) | [28.8](/filings/0001437749-24-016694.md) | [24.9](/filings/0001437749-24-026801.md) | [21.0](/filings/0001437749-24-034965.md) | [18.2](/filings/0001437749-26-009387.md) | [15.0](/filings/0001437749-25-016898.md) | [16.5](/filings/0001437749-25-027002.md) | [30.7](/filings/0001437749-25-034499.md) | [29.7](/filings/0001437749-26-027316.md) | [30.2](/filings/0001437749-26-016748.md) | [26.8](/filings/0001437749-26-027316.md) |
| Current liabilities | $m | [3.6](/filings/0001437749-23-031742.md) | [4.5](/filings/0001437749-25-010250.md) | [3.3](/filings/0001437749-24-016694.md) | [3.3](/filings/0001437749-24-026801.md) | [2.8](/filings/0001437749-24-034965.md) | [2.6](/filings/0001437749-26-009387.md) | [2.0](/filings/0001437749-25-016898.md) | [2.6](/filings/0001437749-25-027002.md) | [3.2](/filings/0001437749-25-034499.md) | [3.8](/filings/0001437749-26-027316.md) | [4.0](/filings/0001437749-26-016748.md) | [4.2](/filings/0001437749-26-027316.md) |
| Total liabilities | $m | [5.0](/filings/0001437749-23-031742.md) | [6.3](/filings/0001437749-25-010250.md) | [12.4](/filings/0001437749-24-016694.md) | [12.1](/filings/0001437749-24-026801.md) | [11.4](/filings/0001437749-24-034965.md) | [10.2](/filings/0001437749-26-009387.md) | [9.4](/filings/0001437749-25-016898.md) | [9.9](/filings/0001437749-25-027002.md) | [11.6](/filings/0001437749-25-034499.md) | [12.7](/filings/0001437749-26-027316.md) | [11.7](/filings/0001437749-26-016748.md) | [12.4](/filings/0001437749-26-027316.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.0](/filings/0001437749-23-031742.md) | [0.0](/filings/0001437749-24-006849.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [18.3](/filings/0001437749-24-034965.md) | [14.1](/filings/0001437749-26-009387.md) | [16.3](/filings/0001437749-25-034499.md) | [12.7](/filings/0001437749-25-034499.md) | [9.6](/filings/0001437749-25-034499.md) | [8.0](/filings/0001437749-26-027316.md) | [5.6](/filings/0001437749-26-027316.md) | [6.6](/filings/0001437749-26-027316.md) | [19.2](/filings/0001437749-25-034499.md) | [17.0](/filings/0001437749-26-027316.md) | [18.5](/filings/0001437749-26-027316.md) | [14.4](/filings/0001437749-26-027316.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,960) d](/filings/0001437749-24-034965.md) | [(3,949) d](/filings/0001437749-25-010250.md) | [(2,883)](/filings/0001437749-25-016898.md) | [(4,610) d](/filings/0001437749-25-027002.md) | [(2,936) d](/filings/0001437749-25-034499.md) | [(2,254) d](/filings/0001437749-26-009387.md) | [(3,470)](/filings/0001437749-26-016748.md) | [(2,948) d](/filings/0001437749-26-027316.md) | [(2,510) d](/filings/0001437749-25-034499.md) | [(2,436) d](/filings/0001437749-26-009387.md) | [(3,400)](/filings/0001437749-26-016748.md) | [(3,924) d](/filings/0001437749-26-027316.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001437749-24-034965.md) | [0.0 d](/filings/0001437749-25-010250.md) | [0.0](/filings/0001437749-24-016694.md) | [0.0 d](/filings/0001437749-24-026801.md) | [0.0 d](/filings/0001437749-24-034965.md) | [0.0 d](/filings/0001437749-25-010250.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2016 (2016-06-30) | Q3 FY2016 (2016-09-30) | Q1 FY2017 (2017-03-31) | Q2 FY2017 (2017-06-30) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.3](/filings/0001437749-17-013509.md) | [45.3](/filings/0001437749-16-040766.md) | [45.3](/filings/0001437749-17-008313.md) | [45.4](/filings/0001437749-17-013509.md) | [119](/filings/0001437749-22-020168.md) | [6.0](/filings/0001437749-22-027307.md) | [7.3](/filings/0001437749-23-013658.md) | [7.4](/filings/0001437749-23-023124.md) | [7.4](/filings/0001437749-23-031742.md) | [10.9](/filings/0001437749-23-013658.md) | [10.9](/filings/0001437749-23-023124.md) | [16.8](/filings/0001437749-23-031742.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 51,905,796 at 2026-08-06, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027316.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.